TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stress hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety of short-term antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of short-term antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygenization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial blood gas analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Treatment Related AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of All-Cause Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With at Least 95% Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Detection of residual breast tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development or worsening of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of severe hypoglycaemic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody titre findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: performance in the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of salt sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of serum TARC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory Volume in one sec (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neovascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Credibility-Expectancy Scale (Credibility Subscale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Client Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of topical timolol in treating infantile hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity in small bowel Crohn disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total blood loss after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of lesions detected as positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knowledge Score (% Correct)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confidence in Choice
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: mortality 30 days
Endpoint domain: Mortality/survival
Primary endpoint: 1 year functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: blood loss at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving enteral nutrition
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from hospital admission to begin enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from hospital admission to achieve target calorie
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress levels assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Tactile Sensitivity Score at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Tactile Sensitivity Score at Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Achieving ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Tear Film Break-Up Time (TFBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective attention as assessed by the Flanker/Reverse Flanker task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Working memory as assessed by the N-back task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inhibition as assessed by the Hearts & Flowers task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relative bioavailability of ABT-072 formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 infection severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transmission of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Psychosocial impacts of COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of the Treatment Using the Medicis Lip Fullness Scale (MLFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in movement errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: feasibility/acceptability of integrated psychosocial care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance with postoperative antibiotic recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnostic accuracy of the PAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metacholine Challenge Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of Kogenate Bayer/FS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Kogenate Bayer/FS
Endpoint domain: Adverse events/effects
Primary endpoint: Flap survival
Endpoint domain: Mortality/survival
Primary endpoint: Severity of the Most Bothersome Symptom of Dyspareunia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WOMAC™ Osteoarthritis Index Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale - VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CT ratio of liver/spleen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 3 and 4 degrees neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperglycemic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in videotaped Welch Lap Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mania Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Opioid Induced Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic capability of NATUS risk results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gaze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of anti fungal duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of the herpes zoster subunit vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC and Cmax of dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neural change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neonatal Developmental Quotient
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Completion time for the supportive care consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of comfort / distress attributed to individual parts of the consultation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects With Blood Phenylalanine < 360 μmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Tolerance to Milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Wound Area Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Qualitative measures of intervention experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time From Start of Labor Induction to Vaginal Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of hepatic chemoembolization
Endpoint domain: Adverse events/effects
Primary endpoint: Time of occurrence of a T4 / T1 ratio > 0.90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Corneal Epithelial Healing Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by Disability of Arm, Shoulder and Hand Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TAC after one week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TAC after Three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response measured by antibody titers to poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving SALT Score of ≤20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pain (to no pain)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and toxicity of ixabepilone and dasatinib
Endpoint domain: Adverse events/effects
Primary endpoint: Infusional and Acute Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline maximum strength in quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ADHD criteria rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (5-year Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Combined vascular events (death, stroke, myocardial infarction, major bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Treatment Response Based on Total PANSS Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease Questionnaire (PDQ-39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Ability to Mobilize After Surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in HbA1c levels from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants performing at least 30% of the recommended Self-Monitoring Blood Glucose tests after 6 months from randomization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self reported ADHD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Obstructive granulation tissue formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Ongoing Pregnancy at Week 8
Endpoint domain: Mortality/survival
Primary endpoint: Coefficient of variation of monoclonal antibody ch14.18 clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of silver in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in UPDRS Parts II+III Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: Average Number of Cigarettes Smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemispatial Neglect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Daily Reflective Nasal Congestion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cure Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pre-pregnancy BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative symptoms on the achalasia questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cortical glutamate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PSAT Sustainability Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Odds ratio for subjects experiencing alanine transaminase (ALT) > ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Odds ratio for subjects experiencing total bilirubin (BIL) > ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: post ERCP pancreatitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of bedside portable endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of bedside portable endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of bedside portable endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who achieve a major molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants who achieve a complete hematologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with treatment-related Neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 2 hour glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of ITCH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with elevated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional rating Index (FRI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Elevated Oral Temperature (>=37.5° C)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With an Injection-site Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Systemic Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of new-onset seizures and/or newly-diagnosed epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of participant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in clinical laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year Annualized Rate of Sight-threatening Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Oxygen Consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Oxford Ankle Foot Questionnaire for Children (OxAFQ-C) Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mobility function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with lung ultrasound score of less than 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knowledge about the child's diagnosis, treatment and follow-up care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Assessed by Numeric Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of T cell infiltration in primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD-L1 expression in primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients able to receive 69Gy as TTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak aortic jet velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Right Insular Cortex Perfusion (ml/100g/Min/mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 Hematological Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Difficult Intubations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blocked area in squared cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Albumincorrected Serum Calcium From Baseline to Week 4, Week 8, and End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24-hour Urinary Calcium Excretion From Baseline to Week 4, Week 8, and End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of tongue strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time with reliable HRV monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Abdominal Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Radiation Dermatitis Severity (RDS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Moist Desquamation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Severity of Skin Reactions Using the Radiation Dermatitis Scale (RDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hemoglobin A1c Level (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in microvascular endothelium dependent dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Small airways obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnosis modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety Disorders Interview Schedule (ADIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV RNA PCR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unsuccessful Treatment Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Human Neutrophil Peptide Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutrophil Engraftment Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: symptomatic lymph cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes